Molecular Formula | C9H11NO |
Molar Mass | 149.19 |
Density | 1.0753 (rough estimate) |
Melting Point | 118-121°C(lit.) |
Boling Point | 270.27°C (rough estimate) |
Specific Rotation(α) | 44.5 º (c=1, methanol) |
Flash Point | 129.207°C |
Water Solubility | soluble |
Solubility | soluble in Methanol |
Vapor Presure | 0.001mmHg at 25°C |
Appearance | White to light yellow crystal powder |
Color | White to light beige |
BRN | 2803743 |
pKa | 14.79±0.40(Predicted) |
Storage Condition | Keep in dark place,Inert atmosphere,Room temperature |
Refractive Index | 43 ° (C=1, MeOH) |
MDL | MFCD00216656 |
Physical and Chemical Properties | Melting Point 117-121°C specific rotation 44.5 ° (c = 1, methanol) water-soluble solution melting point 118-121°C(lit.) specific optical rotation 44.5 ° (c = 1, methanol) refractive index 43 ° (C = 1, MeOH) solubility in water |
Use | Used as a drug indinavir Intermediate |
Risk Codes | R36/37/38 - Irritating to eyes, respiratory system and skin. R20/21/22 - Harmful by inhalation, in contact with skin and if swallowed. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. |
UN IDs | 2811 |
WGK Germany | 3 |
FLUKA BRAND F CODES | 10-23 |
TSCA | No |
HS Code | 29061990 |
Use | (1R,2S)-1-amino-2-indanol can be used to synthesize indinavir intermediates, indinavir can Inhibit proteases encoded by human immunodeficiency virus (HIV), especially certain oligopeptide analogs. These compounds can be used to prevent HIV infection, treat acquired immunodeficiency syndrome (AIDS) caused by HIV infection and treatment. These compounds can also be used to inhibit angiotensin progenase and other proteases. Used as indinavir intermediate. used as drug indinavir intermediate |